HRP20140946T1 - Terapeutske kompozicije koje sadrže rilpivirin hcl i tenovofir dizoproksil fumarat - Google Patents
Terapeutske kompozicije koje sadrže rilpivirin hcl i tenovofir dizoproksil fumarat Download PDFInfo
- Publication number
- HRP20140946T1 HRP20140946T1 HRP20140946AT HRP20140946T HRP20140946T1 HR P20140946 T1 HRP20140946 T1 HR P20140946T1 HR P20140946A T HRP20140946A T HR P20140946AT HR P20140946 T HRP20140946 T HR P20140946T HR P20140946 T1 HRP20140946 T1 HR P20140946T1
- Authority
- HR
- Croatia
- Prior art keywords
- layer
- tablet
- rilpivirine
- image
- sodium
- Prior art date
Links
- 229960002814 rilpivirine Drugs 0.000 title claims 9
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 title claims 9
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 title claims 4
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title claims 4
- 239000000203 mixture Substances 0.000 title claims 3
- 230000001225 therapeutic effect Effects 0.000 title claims 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 6
- 229960001681 croscarmellose sodium Drugs 0.000 claims 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 5
- 229960001021 lactose monohydrate Drugs 0.000 claims 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 5
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 229960000366 emtricitabine Drugs 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 229940057948 magnesium stearate Drugs 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 229940068977 polysorbate 20 Drugs 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 229960004481 rilpivirine hydrochloride Drugs 0.000 claims 2
- KZVVGZKAVZUACK-BJILWQEISA-N rilpivirine hydrochloride Chemical group Cl.CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 KZVVGZKAVZUACK-BJILWQEISA-N 0.000 claims 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 239000000908 ammonium hydroxide Substances 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- -1 dihydroaluminum Chemical compound 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- MSJMDZAOKORVFC-UAIGNFCESA-L disodium maleate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C/C([O-])=O MSJMDZAOKORVFC-UAIGNFCESA-L 0.000 claims 1
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- 239000001095 magnesium carbonate Substances 0.000 claims 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims 1
- 239000002897 polymer film coating Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 235000011083 sodium citrates Nutrition 0.000 claims 1
- 229940074404 sodium succinate Drugs 0.000 claims 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims 1
- 239000001433 sodium tartrate Substances 0.000 claims 1
- 229960002167 sodium tartrate Drugs 0.000 claims 1
- 235000011004 sodium tartrates Nutrition 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (23)
1. Tableta koja sadrži prvi sloj i drugi sloj pri čemu; a) prvi sloj sadrži rilpivirin HCl i suštinski je bez tenofovir dizoproksil fumarata, i pri čemu manje od oko 12.2 masenog postotka prvog sloja je rilpivirin HCl; b) drugi sloj sadrži tenofovir dizoproksil fumarat, i i suštinski je bez rilpivirin HCl; i c) tableta dalje sadrži emtricitabin.
2. Tableta zahtjeva 1 gdje prvi sloj ne sadrži emtricitabin.
3. Tableta zahtjeva 1 ili 2 koja sadrži 27.5 ± 1.4 mg rilpivirin HCl.
4. Tableta bilo kojeg od zahtjeva 1-3 koja sadrži 200 ± 10.0 mg emtricitabina.
5. Tableta bilo kojeg od zahtjeva 1-4 koja sadrži 300 ± 15.0 mg tenofovir dizoproksil fumarata.
6. Tableta bilo kojeg od zahtjeva 1-5 gdje prvi sloj dalje sadrži jedan ili više rastvarača, sredstva za raspadanje, sredstva za vezivanje, ili lubrikante.
7. Tableta zahtjeva 6 gdje je ukupna masa prvog sloja 275 ± 75 mg, prije svega veća od 225 mg, a posebno je 275 ± 50 mg.
8. Tableta bilo kojeg od zahtjeva 1-7 gdje prvi sloj sadrži sredstvo za povećanje baznosti koje je prvenstveno izabrano od kroskarmeloza-natrija, kalcijevog karbonata, natrijevog hidroksida, aluminijevog oksida, hidroksida alkalnih metala, hidroksida zemnoalkalnih metala, aluminijevog hidroksida, dihidroaluminija, natrijevog karbonata, amonijevog hidroksida, magnezijevog karbonata, magnezijevog stearata, piperazina, natrijevog acetata, natrijevog citrata, natrijevog tartarata, natrijevog maleata, i natrijevog sukcinata i njihovih mikstura.
9. Tableta bilo kojeg od zahtjeva 1-8 gdje prvi sloj sadrži natrijevu kroskarmelozu, i polisorbat 20 i posebno sadrži laktozu monohidrat, povidon, natrijevu kroskarmelozu, polisorbat 20, mikrokristalnu celulozu, i megnezijev stearat.
10. Tableta bilo kojeg od zahtjeva 1-9 gdje drugi sloj sadrži mikrokristalnu celulozu i natrijevu kroskarmelozu, a posebno sadrži laktozu monohidrat, pregelatinizirani škrob, mikrokristalnu celulozu, natrijevu kroskarmelozu, i magnezijev stearat.
11. Tableta bilo kojeg od zahtjeva 1-10 gdje je prvi sloj u kontaktu sa drugim slojem.
12. Tableta bilo kojeg od zahtjeva 1-10 koja dalje sadrži treći sloj koji je između i koji razdvaja prvi sloj i drugi sloj.
13. Tableta zahtjeva 12 gdje treći sloj sadrži laktozu monohidrat i/ili mikrokristalnu celulozu.
14. Tableta bilo kojeg od zahtjeva 1-5 gdje je prvi sloj omotač od polimernog filma koji je u kontaktu sa drugim slojem i poželjno potpuno prekriva drugi sloj.
15. Tableta zahtjeva 2 gdje prvi sloj sadrži:
[image]
a drugi sloj sadrži:
[image]
ili
gdje se prvi sloj sastoji od:
[image]
a drugi sloj se sastoji od:
[image]
16. Tableta zahtjeva 12 gdje se prvi sloj sastoji od:
[image]
drugi sloj se sastoji od:
[image]
a treći sloj sadrži 150 ± 8.0 mg mikrokristalne celuloze ili laktoza monohidrata, ili njihove miksture.
17. Tableta bilo kojeg od zahtjeva 1-13 i 15-16 koja dalje sadrži film omotač koji poželjno sadrži 34 ± 12 mg Opadry II Purple 33G100000.
18. Tableta koja ima prvi sloj koji se sastoji od:
[image]
a drugi sloj se sastoji od:
[image]
A omotač se sastoji od:
[image]
19. Tableta bilo kojeg od zahtjeva 1-13 gdje najmanje oko 5.4 masenog postotka prvog sloja je natrijeva kroskarmeloza i najmanje oko 63.3 postotka mase prvog sloja je laktoza monohidrat.
20. Tableta bilo kojeg od zahtjeva 1-14 gdje je manje od oko 12 postotka mase prvog sloja rilpivirin hidrohlorid.
21. Tableta zahtjeva 1 gdje prvi sloj sadrži 27.5 ± 1.4 mg rilpivirin hidrohlorida i gdje je totalna masa prvog sloja najmanje oko 230 mg.
22. Tableta kao što je opisano u bilo kojem od zahtjeva 1-21 za primjenu u profilaktičkom ili terapeutskom tretmanu HIV infekcije, gdje rilpivirin AUC (area under the curve-površina ispod krivulje) koji je postignut primjenom kod čovjeka uz ishranu nije više od oko 25% veći od rilpivirin AUC koji je postignut primjenom kod čovjeka na dijeti ili gdje rilpivirin Cmaxkoji je postignut primjenom kod čovjeka uz ishranu nije više od oko 25% veći od rilpivirin Cmax koji je postignut primjenom kod čovjeka na dijeti.
23. Tableta kao što je opisano u bilo kojem od zahtjeva 1-21 za primjenu u profilaktičkom ili terapeutskom tretmanu HIV infekcije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41560010P | 2010-11-19 | 2010-11-19 | |
| EP11791161.0A EP2640362B2 (en) | 2010-11-19 | 2011-11-18 | Therapeutic compositions comprising rilpivirin hcl and tenovofir disoproxil fumarate |
| PCT/US2011/061515 WO2012068535A1 (en) | 2010-11-19 | 2011-11-18 | Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140946T1 true HRP20140946T1 (hr) | 2015-02-13 |
Family
ID=45094284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140946AT HRP20140946T1 (hr) | 2010-11-19 | 2014-10-01 | Terapeutske kompozicije koje sadrže rilpivirin hcl i tenovofir dizoproksil fumarat |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US10857102B2 (hr) |
| EP (2) | EP2826466A1 (hr) |
| JP (2) | JP2014500261A (hr) |
| KR (1) | KR101923103B1 (hr) |
| CN (2) | CN103491948B (hr) |
| AP (1) | AP3816A (hr) |
| AR (2) | AR084500A1 (hr) |
| AU (3) | AU2011329642B2 (hr) |
| BR (1) | BR112013012245B1 (hr) |
| CA (1) | CA2818097C (hr) |
| CL (1) | CL2013001402A1 (hr) |
| CO (1) | CO6761300A2 (hr) |
| CR (1) | CR20130293A (hr) |
| DK (1) | DK2640362T4 (hr) |
| EA (2) | EA201691695A1 (hr) |
| EC (2) | ECSP13012700A (hr) |
| ES (1) | ES2524408T5 (hr) |
| HK (2) | HK1190064A1 (hr) |
| HR (1) | HRP20140946T1 (hr) |
| IL (1) | IL226300B (hr) |
| MA (1) | MA34735B1 (hr) |
| ME (1) | ME01980B (hr) |
| MX (1) | MX347512B (hr) |
| MY (1) | MY185604A (hr) |
| NZ (1) | NZ610729A (hr) |
| PE (3) | PE20211657A1 (hr) |
| PL (1) | PL2640362T5 (hr) |
| PT (1) | PT2640362E (hr) |
| RS (1) | RS53691B1 (hr) |
| SG (3) | SG190333A1 (hr) |
| SM (1) | SMT201400150B (hr) |
| TW (1) | TWI556840B (hr) |
| UA (1) | UA114075C2 (hr) |
| WO (1) | WO2012068535A1 (hr) |
| ZA (1) | ZA201304481B (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040224916A1 (en) | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| CN103491948B (zh) | 2010-11-19 | 2016-11-02 | 吉利德科学公司 | 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物 |
| UY34262A (es) | 2011-08-16 | 2013-04-05 | Gilead Sciences Inc | Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos |
| CA2779052A1 (en) * | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
| CA3012242C (en) | 2012-12-21 | 2021-11-02 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| WO2015014737A1 (en) * | 2013-07-29 | 2015-02-05 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Multilayer tablet formulations comprising tenofovir and entecavir |
| CZ2013985A3 (cs) * | 2013-12-09 | 2015-06-17 | Zentiva, K.S. | Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát |
| WO2015152433A1 (en) * | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
| EP3236972B1 (en) | 2014-12-26 | 2021-07-28 | Emory University | Anti-viral n4-hydroxycytidine derivatives |
| US9839212B2 (en) | 2015-04-16 | 2017-12-12 | Bio-Lab, Inc. | Multicomponent and multilayer compacted tablets |
| CA2921336A1 (en) * | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| KR20170003063A (ko) * | 2015-06-30 | 2017-01-09 | 한미약품 주식회사 | 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법 |
| MX2018005729A (es) | 2015-11-09 | 2018-08-09 | Gilead Sciences Inc | Composiciones terapeuticas para tratamiento del virus de inmunodeficiencia humana. |
| US20190060325A1 (en) * | 2016-04-08 | 2019-02-28 | Shionogi & Co., Ltd. | Stabilized solid dosage form |
| TR201617448A2 (tr) * | 2016-11-29 | 2018-06-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler |
| US10561614B2 (en) * | 2017-01-27 | 2020-02-18 | Steerlife India Private Limited | Tenofovir granules |
| RU2755710C2 (ru) * | 2017-06-30 | 2021-09-20 | Вайв Хелткер Компани | Комбинация, ее применение и способы лечения с использованием указанной комбинации |
| CA3082191C (en) | 2017-12-07 | 2021-09-21 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| US20210000823A1 (en) * | 2019-07-03 | 2021-01-07 | Janssen Sciences Ireland Unlimited Company | Methods of treating hiv |
| CN112137981A (zh) * | 2020-11-02 | 2020-12-29 | 成都晶富医药科技有限公司 | 富马酸丙酚替诺福韦片及其制备工艺 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ241625A (en) | 1991-02-22 | 1996-03-26 | Univ Emory | 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers |
| MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| AU2002359518A1 (en) | 2001-11-27 | 2003-06-10 | Bristol-Myers Squibb Company | Efavirenz tablet formulation having unique biopharmaceutical characteristics |
| US20040224916A1 (en) | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| KR101284361B1 (ko) | 2004-09-02 | 2013-07-15 | 얀센 파마슈티카 엔.브이. | 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드 |
| ATE508748T1 (de) | 2004-09-02 | 2011-05-15 | Janssen Pharmaceutica Nv | Salz von 4-ää4-ää4-(2-cyanoethenyl)-2,6- dimethylphenylüaminoü-2- pyrimidinylüaminoübenzonitril. |
| TWI375560B (en) * | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| WO2007047371A2 (en) | 2005-10-14 | 2007-04-26 | Microdose Technologies, Inc. | Pharmaceutical packaging of an oral dosage combination |
| ATE474560T1 (de) | 2005-12-14 | 2010-08-15 | Cipla Ltd | Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit |
| PT2487166T (pt) * | 2007-02-23 | 2016-10-17 | Gilead Sciences Inc | Moduladores de propriedades farmacocinéticas de agentes terapêuticos |
| US20080286344A1 (en) | 2007-05-16 | 2008-11-20 | Olivia Darmuzey | Solid form |
| WO2008140461A1 (en) | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
| WO2008143500A1 (en) | 2007-05-22 | 2008-11-27 | Ultimorphix Technologies B.V. | Tenofovir disoproxil hemi-fumaric acid co-crystal |
| WO2009037449A1 (en) | 2007-09-18 | 2009-03-26 | Cipla Limited | Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors |
| WO2009106960A2 (en) | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable compositions of lamivudine, tenofovir and efavirenz |
| SI2296633T1 (sl) | 2008-05-02 | 2015-11-30 | Gilead Sciences, Inc. | Uporaba trdnih nosilnih delcev za izboljšanje predelovalnih sposobnosti farmacevtskega sredstva |
| HUE025822T2 (en) | 2009-02-06 | 2016-04-28 | Gilead Sciences Inc | Dual layer tablets containing Elvitegravir, Cobicistat, Emtricitabine and Tenofovir |
| CA2773772C (en) | 2009-09-21 | 2018-06-26 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| WO2011077100A1 (en) | 2009-12-24 | 2011-06-30 | Cipla Limited | Antiretroviral composition |
| CN103491948B (zh) | 2010-11-19 | 2016-11-02 | 吉利德科学公司 | 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物 |
-
2011
- 2011-11-18 CN CN201180063666.6A patent/CN103491948B/zh active Active
- 2011-11-18 UA UAA201306403A patent/UA114075C2/uk unknown
- 2011-11-18 MY MYPI2016001764A patent/MY185604A/en unknown
- 2011-11-18 SG SG2013038484A patent/SG190333A1/en unknown
- 2011-11-18 NZ NZ610729A patent/NZ610729A/en unknown
- 2011-11-18 BR BR112013012245-5A patent/BR112013012245B1/pt active IP Right Grant
- 2011-11-18 SG SG10201912527XA patent/SG10201912527XA/en unknown
- 2011-11-18 CN CN201610900183.1A patent/CN106511357A/zh active Pending
- 2011-11-18 PE PE2021000720A patent/PE20211657A1/es unknown
- 2011-11-18 AP AP2013006931A patent/AP3816A/en active
- 2011-11-18 RS RS20140668A patent/RS53691B1/en unknown
- 2011-11-18 ES ES11791161T patent/ES2524408T5/es active Active
- 2011-11-18 EP EP14183494.5A patent/EP2826466A1/en not_active Withdrawn
- 2011-11-18 DK DK11791161.0T patent/DK2640362T4/da active
- 2011-11-18 US US13/988,072 patent/US10857102B2/en active Active
- 2011-11-18 SG SG10201509521WA patent/SG10201509521WA/en unknown
- 2011-11-18 MX MX2013005669A patent/MX347512B/es active IP Right Grant
- 2011-11-18 EP EP11791161.0A patent/EP2640362B2/en active Active
- 2011-11-18 JP JP2013540085A patent/JP2014500261A/ja not_active Withdrawn
- 2011-11-18 PT PT117911610T patent/PT2640362E/pt unknown
- 2011-11-18 PE PE2016002828A patent/PE20170521A1/es unknown
- 2011-11-18 EA EA201691695A patent/EA201691695A1/ru unknown
- 2011-11-18 AR ARP110104318A patent/AR084500A1/es not_active Application Discontinuation
- 2011-11-18 ME MEP-2014-150A patent/ME01980B/me unknown
- 2011-11-18 PL PL11791161T patent/PL2640362T5/pl unknown
- 2011-11-18 AU AU2011329642A patent/AU2011329642B2/en active Active
- 2011-11-18 WO PCT/US2011/061515 patent/WO2012068535A1/en active Application Filing
- 2011-11-18 EA EA201390651A patent/EA025852B1/ru unknown
- 2011-11-18 PE PE2013001214A patent/PE20140163A1/es not_active Application Discontinuation
- 2011-11-18 TW TW100142311A patent/TWI556840B/zh active
- 2011-11-18 CA CA2818097A patent/CA2818097C/en active Active
- 2011-11-18 KR KR1020137015719A patent/KR101923103B1/ko active IP Right Grant
-
2013
- 2013-05-12 IL IL226300A patent/IL226300B/en active IP Right Grant
- 2013-05-17 CL CL2013001402A patent/CL2013001402A1/es unknown
- 2013-05-28 CO CO13130615A patent/CO6761300A2/es unknown
- 2013-06-14 MA MA36010A patent/MA34735B1/fr unknown
- 2013-06-17 CR CR20130293A patent/CR20130293A/es unknown
- 2013-06-18 EC ECSP13012700 patent/ECSP13012700A/es unknown
- 2013-06-18 ZA ZA2013/04481A patent/ZA201304481B/en unknown
-
2014
- 2014-03-21 HK HK14102832.2A patent/HK1190064A1/xx active IP Right Maintenance
- 2014-03-21 HK HK15106347.0A patent/HK1206592A1/xx unknown
- 2014-10-01 HR HRP20140946AT patent/HRP20140946T1/hr unknown
- 2014-10-16 SM SM201400150T patent/SMT201400150B/xx unknown
-
2015
- 2015-04-20 JP JP2015085594A patent/JP6138851B2/ja active Active
-
2016
- 2016-07-29 AU AU2016208417A patent/AU2016208417B2/en active Active
-
2018
- 2018-04-16 AU AU2018202635A patent/AU2018202635A1/en not_active Abandoned
-
2019
- 2019-10-30 EC ECSENADI201978196A patent/ECSP19078196A/es unknown
-
2020
- 2020-11-19 AR ARP200103214A patent/AR123409A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140946T1 (hr) | Terapeutske kompozicije koje sadrže rilpivirin hcl i tenovofir dizoproksil fumarat | |
| JP2015131853A5 (hr) | ||
| HRP20120633T1 (hr) | Formulacija rasagilina s odgođenim oslobađanjem | |
| AU2011237122B2 (en) | Easily dosable solid preparation | |
| IL179454A (en) | Formulation of coated tablet and method | |
| JP2006516570A5 (hr) | ||
| DK2273985T3 (en) | Capsule for the prevention of cardiovascular diseases | |
| JP2016518452A5 (hr) | ||
| JP2015506377A5 (hr) | ||
| RU96118271A (ru) | Композиции, содержащие тонкоизмельченный небиволол | |
| US20110123609A1 (en) | Multiple unit dosage form of niacin | |
| KR20150132399A (ko) | 에베롤리무스를 포함하는 제약 조성물 | |
| EP3041511A2 (en) | Compositions of eltrombopag | |
| WO2014142607A1 (ko) | 약제학적 복합제제 | |
| RU2009102443A (ru) | Фармацевтический препарат для контрацепции и для предотвращения риска врожденных пороков развития | |
| MXPA02012727A (es) | Preparados de liberacion retardada de antibioticos de quinolona y procedimiento para su preparacion. | |
| KR20110130441A (ko) | 고형 제제 | |
| RU2016150178A (ru) | Твёрдая дисперсия аллисартана изопроксила и фармацевтическая композиция | |
| JP2018538289A (ja) | アプレミラスト徐放性製剤 | |
| JP2019526591A (ja) | ロスバスタチン及びエゼチミブを含む医薬組成物並びにその調製方法 | |
| JP2016530238A5 (hr) | ||
| JP2016104729A (ja) | 湿製錠剤、及び湿製錠剤の製造方法 | |
| JP2020511419A5 (hr) | ||
| KR20120006983A (ko) | 고형 제제 | |
| WO2010120963A1 (en) | Tablet formulation for p38 inhibitor and method |